Investment Rating - The report maintains a "Buy" rating for the company [6]. Core Insights - The company achieved a total revenue of 3.022 billion yuan in 2024, representing a year-on-year growth of 30.1%, and an adjusted net profit of 400 million yuan, up 31.4% year-on-year [1][4]. - Key operational metrics such as outpatient visits, customer retention rate, average spending per visit, and customer unit price have all improved in 2024, indicating robust operational performance [2]. - The company is developing an "AI avatar" of renowned doctors, leveraging extensive data sources and deep learning algorithms to replicate expert diagnostic capabilities, which is expected to enhance service delivery and accelerate revenue growth [3][4]. Financial Performance and Forecast - The company’s revenue is projected to grow from 3.022 billion yuan in 2024 to 5.902 billion yuan by 2027, with a compound annual growth rate (CAGR) of approximately 24.65% [4][10]. - Adjusted net profit is forecasted to increase from 400 million yuan in 2024 to 708 million yuan in 2027, reflecting a steady growth trajectory [4][10]. - The report anticipates adjusted earnings per share (EPS) to rise from 1.64 yuan in 2024 to 2.95 yuan in 2027 [4][10]. Operational Metrics - In 2024, the company recorded 5.411 million outpatient visits and a customer retention rate of 67.1%, up from 65.2% in 2023 [2]. - The average spending per visit increased from 541 yuan to 559 yuan, showcasing improved customer engagement and service value [2]. Strategic Initiatives - The company is actively pursuing mergers and acquisitions, as well as expanding its physical presence, with a total of 79 clinics established in China and Singapore by the end of 2024 [2][4]. - The anticipated launch of several "AI avatars" of top doctors in July 2025 is expected to significantly enhance the company's service capabilities and operational efficiency [3].
固生堂（02273）：2024年报点评：业绩快速增长，名医“AI分身”值得期待